中文摘要：

目的：研究12-脂氧合酶（12-lipoxygenase，12-LOX）在神经胶质瘤中的表达及其临床意义。方法：免疫组织化学法检测40例神经胶质瘤组织和10例正常脑组织中12-LOX表达，结合临床随访资料探讨其表达与预后的相关性。结果：正常脑组织中12-LOX呈弱阳性表达，神经胶质瘤组织中强阳性表达率为72．5％，差异有统计学意义（P〈0．05）。12-LOX强阳性表达与神经胶质瘤病理级别相关，差异有统计学意义（P=0．012），与患者性别、年龄、肿瘤大小、KPS评分无关。12-LOX强阳性表达患者中位无瘤生存期明显低于与弱阳性表达患者（P〈0．05）。结论：12-LOX在神经胶质瘤中异常表达，其表达差异与神经胶质瘤的病理级别相关．与预后密切相关。

英文摘要：

Objective： To investigate the expression and clinical significance of 12-1ipoxygenase （12-LOX） in glioma. Methods： 12-LOX expression in 40 glioma cases and 10 normal human-brain tissues was assayed by immunohistochemistry. Clinicopathological data were analyzed to reveal the association between 12-LOX expression and prognosis of glioma patients. Results： 12-LOX was weak- ly expressed in the normal human brain tissues, whereas 12-LOX was strongly expressed （72.5%） in glioma tissues （P〈0.05）. The strong 12-LOX expression was correlated with the histopathological grading of glioma （P=0.012）, whereas 12-LOX expression was not correlated with factors such as patient gender and age, tumor size, and Karnofsky Performance Score. Median survival time was longer in the group with low 12-LOX expression （25.6 months） than in the group with high 12-LOX expression （13.2 months） （P〈0.05）. Con- clusion： Abnormal 12-LOX expression is implicated in glioma. 12-LOX expression was correlated with the histopathological grading of ~lioma and was closely associated with patient prognosis.